# Belite Bio, Inc (BLTE)

Source page: https://stoqly.net/companies/blte

- **Ticker:** BLTE (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001889109
- **Latest annual report:** 20-F filed 2026-03-31 (https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm)
- **Data updated:** 2026-11-09

## Key figures

- **Last close:** $157.69 on 2026-11-09 (+2.27% on the day)
- **Market cap:** $5.3B
- **EPS, trailing 12 months:** −$2.31
- **Free cash flow:** −$37.1M
- **Return on equity:** −16.9%
- **Change in share count:** +9.8%
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $32.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/blte/figures.csv

| US$ millions | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|
| Operating income | -6 | -10 | -13 | -32 | -40 | -84 |
| Net income | -6 | -10 | -13 | -32 | -36 | -78 |
| Diluted EPS (US$) | -0.65 | -1.01 | -0.63 | -1.19 | -1.18 | -2.31 |
| Operating cash flow | -4 | -7 | -11 | -30 | -29 | -37 |
| Free cash flow | — | -8 | -12 | -30 | -29 | -37 |
| Cash | 26 | 17 | 42 | 88 | 36 | 353 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.